TerminatedPHASE2, PHASE3NCT00507429
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
Studying Anaplastic thyroid carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mateon Therapeutics
- Principal Investigator
- Julie A. Sosa, MD, FACSYale University School of Medicine, New Haven, CT
- Intervention
- CA4P(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2011
Study locations (30)
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of Colorado Cancer Center, Aurora, Colorado, United States
- Yale University, School of Medicine, New Haven, Connecticut, United States
- Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
- Sidney Kimmel Comprehensive Cancer Care Center at John Hopkins, Baltimore, Maryland, United States
- University of Minnesota Otolaryngology Department, Minneapolis, Minnesota, United States
- Ireland Cancer Center/Division od Hematology, Cleveland, Ohio, United States
- Oregon Health and Science University, Portland, Oregon, United States
- University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
- West Virginia University, Morgantown, West Virginia, United States
- Belarus National Medical University, Minsk, Belarus
- Regional Oncology Dispensary with Inpatient Sector, Plodiv, Bulgaria
- Specialized Hospital for Active Treatment of Oncology, Sofia, Bulgaria
- Universtiy Multiprofile Hospital, ISUI, Clinic of Oncotherapy, Sofia, Bulgaria
- University Hospital, Cairo, Cairo, Egypt
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00507429 on ClinicalTrials.govOther trials for Anaplastic thyroid carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06790706IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersHospices Civils de Lyon
- RECRUITINGPHASE1NCT06902376XL092 and Cemiplimab in BRAF WT Thyroid CancerUNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06235216Sacituzumab govitEcan in THYroid CancersGrupo Espanol de Tumores Neuroendocrinos
- RECRUITINGPHASE2NCT06362694Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF TherapySaint Petersburg State University, Russia
- RECRUITINGPHASE2NCT06374602Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerSaint Petersburg State University, Russia
- RECRUITINGPHASE2NCT06007924A Study of Avutometinib and Defactinib in People With Thyroid CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06079333NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)Leiden University Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT05453799Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid CancerNorthwestern University